BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paul B, Lipe B, Ocio EM, Usmani SZ. Induction Therapy for Newly Diagnosed Multiple Myeloma. Am Soc Clin Oncol Educ Book 2019;39:e176-86. [PMID: 31099624 DOI: 10.1200/EDBK_238527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Costa BA, Mouhieddine TH, Richter J. What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. Target Oncol 2022. [PMID: 35771402 DOI: 10.1007/s11523-022-00897-8] [Reference Citation Analysis]
2 Jazowski SA, Wilson L, Dusetzina SB, Zafar SY, Zullig LL. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma. JAMA Netw Open 2022;5:e2215720. [PMID: 35671056 DOI: 10.1001/jamanetworkopen.2022.15720] [Reference Citation Analysis]
3 Nunnelee J, Cottini F, Zhao Q, Faisal MS, Elder P, Rosko A, Bumma N, Khan A, Devarakonda S, Benson DM, Efebera Y, Sharma N. Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience. Cancers (Basel) 2022;14:2277. [PMID: 35565406 DOI: 10.3390/cancers14092277] [Reference Citation Analysis]
4 Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S, Zhu M, Chang H, Gong F, Zhou J, Chen G, Pan J, Liu D, Zhu X, Tang F, Liu M, Liu W, Yao F, Yu L, Wu D, Fu C. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol 2022;97:537-47. [PMID: 35114022 DOI: 10.1002/ajh.26486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Firer MA, Shapira MY, Luboshits G. The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma. Cancers (Basel) 2021;13:4090. [PMID: 34439244 DOI: 10.3390/cancers13164090] [Reference Citation Analysis]
6 Voorhees PM, Rodriguez C, Reeves B, Nathwani N, Costa LJ, Lutska Y, Bobba P, Hoehn D, Pei H, Ukropec J, Qi M, Lin TS, Richardson PG. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv 2021;5:1092-6. [PMID: 33606004 DOI: 10.1182/bloodadvances.2020003642] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liu J, Pandya P, Afshar S. Therapeutic Advances in Oncology. Int J Mol Sci 2021;22:2008. [PMID: 33670524 DOI: 10.3390/ijms22042008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Nagai Y, Mimura N, Rizq O, Isshiki Y, Oshima M, Rizk M, Saraya A, Koide S, Nakajima-Takagi Y, Miyota M, Chiba T, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Nakaseko C, Lennox W, Sheedy J, Weetall M, Yokote K, Iwama A, Sakaida E. The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells. Sci Rep 2021;11:2074. [PMID: 33483574 DOI: 10.1038/s41598-021-81577-x] [Reference Citation Analysis]
9 Ge X, Jiang W, Jiang Y, Lv X, Liu X, Wang X. Expression and Importance of TMED2 in Multiple Myeloma Cells. Cancer Manag Res 2020;12:12895-903. [PMID: 33364837 DOI: 10.2147/CMAR.S278570] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Abonour R, Rifkin RM, Gasparetto C, Toomey K, Durie BGM, Hardin JW, Terebelo HR, Jagannath S, Narang M, Ailawadhi S, Omel JL, Lee HC, Srinivasan S, Kitali A, Agarwal A, Wagner L; CONNECT MM Registry Investigators. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry. Br J Haematol 2021;193:93-100. [PMID: 33118614 DOI: 10.1111/bjh.17131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Montefusco V, Martinelli G, Cerchione C. How I manage frontline transplant-eligible multiple myeloma in Italy. Hematol Rep 2020;12:8954. [PMID: 33042503 DOI: 10.4081/hr.2020.8954] [Reference Citation Analysis]